• Users Online: 1131
  • Print this page
  • Email this page
Year : 2021  |  Volume : 11  |  Issue : 4  |  Page : 172-178

Newer oral anticoagulants in venous thromboembolism

1 Senior Consultant Cardiology, Indraprastha Apollo Hospital, New Delhi, India
2 Associate Consultant Cardiology, Indraprastha Apollo Hospital, New Delhi, India

Correspondence Address:
Dr. Ranjan Modi
Indraprastha Apollo Hospitals, New Delhi - 110 076
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jicc.jicc_73_20

Rights and Permissions

Venous thromboembolism (VTE) is an important medical condition for morbidity and mortality. Adequate anticoagulant treatment is necessary to reduce short- and long-term VTE related conditions. In the past low molecular weight heparin (LMWH) and Vitamin K antagonists (VKAs) have been the mainstay of anticoagulation therapy for VTE patients. The patients require frequent monitoring with INR to keep balance between effectiveness and safety in clinical practice. NOACs have been the main stay of treatment in conditions requiring effective anticoagulation. They may prove to do the same in VTE. This article analyses, the present literature on use of NOACs in VTE.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded90    
    Comments [Add]    

Recommend this journal